Details for New Drug Application (NDA): 072205
✉ Email this page to a colleague
NDA 072205 describes LOXAPINE SUCCINATE, which is a drug marketed by Elite Labs Inc, Lannett Co Inc, Rising, and Watson Labs, and is included in seven NDAs. It is available from six suppliers. Additional details are available on the LOXAPINE SUCCINATE profile page.
The generic ingredient in LOXAPINE SUCCINATE is loxapine succinate. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the loxapine succinate profile page.
The generic ingredient in LOXAPINE SUCCINATE is loxapine succinate. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the loxapine succinate profile page.
Summary for 072205
| Tradename: | LOXAPINE SUCCINATE |
| Applicant: | Watson Labs |
| Ingredient: | loxapine succinate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 072205
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LOXAPINE SUCCINATE | loxapine succinate | CAPSULE;ORAL | 072205 | ANDA | Actavis Pharma, Inc. | 0591-0370 | 0591-0370-01 | 100 CAPSULE in 1 BOTTLE, PLASTIC (0591-0370-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Jun 15, 1988 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
